Cyfuse Biomedical
Founded Year
2010Stage
IPO | IPOTotal Raised
$28.95MDate of IPO
12/1/2022About Cyfuse Biomedical
Cyfuse Biomedical is focused on the development, manufacturing, and sales of regenerative medicine-related products. The company aims to contribute to the medical fields of regenerative medicine and drug discovery by generating steric tissues and organs. The company has developed Regenova, a 3D bioprinter.
Missing: Cyfuse Biomedical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cyfuse Biomedical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cyfuse Biomedical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cyfuse Biomedical is included in 5 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
242 items
Medical Device New Products & Services Tech MM (August 2021)
Biopharma Tech
1,568 items
Advanced Manufacturing
4,183 items
Companies focused on the technologies to increase manufacturing productivity, ranging from automation & robotics to AR/VR to factory analytics & AI, plus many more.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Cyfuse Biomedical Patents
Cyfuse Biomedical has filed 15 patents.
The 3 most popular patent topics include:
- Cell biology
- Stem cells
- Biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/30/2017 | 3/30/2021 | Stem cells, Cell biology, Developmental biology, Embryology, Biotechnology | Grant |
Application Date | 10/30/2017 |
|---|---|
Grant Date | 3/30/2021 |
Title | |
Related Topics | Stem cells, Cell biology, Developmental biology, Embryology, Biotechnology |
Status | Grant |
Latest Cyfuse Biomedical News
Feb 21, 2023
The global market for Human Liver Models estimated at US$226.9 Million in the year 2022, is projected to reach a revised size of US$474.3 Million by 2030, growing at a CAGR of 9.7% over the analysis period 2022-2030. Liver Organoids, one of the segments analyzed in the report, is projected to record a 9.5% CAGR and reach US$250.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Liver-On-A-Chip segment is readjusted to a revised 11.1% CAGR for the next 8-year period. The U.S. Market is Estimated at $61.8 Million, While China is Forecast to Grow at 13.5% CAGR The Human Liver Models market in the U.S. is estimated at US$61.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$104.7 Million by the year 2030 trailing a CAGR of 13.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 7.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$69 Million by the year 2030. Select Competitors (Total 42 Featured) - Ascendance Biotechnology, Inc.
Cyfuse Biomedical Frequently Asked Questions (FAQ)
When was Cyfuse Biomedical founded?
Cyfuse Biomedical was founded in 2010.
Where is Cyfuse Biomedical's headquarters?
Cyfuse Biomedical's headquarters is located at ICN Bldg. 5A, Tokyo.
What is Cyfuse Biomedical's latest funding round?
Cyfuse Biomedical's latest funding round is IPO.
How much did Cyfuse Biomedical raise?
Cyfuse Biomedical raised a total of $28.95M.
Who are the investors of Cyfuse Biomedical?
Investors of Cyfuse Biomedical include Fujimori Kogyo, Iwatani, Mitsubishi UFJ Lease & Finance, Taiyo Holdings, Nissay Capital and 18 more.
Who are Cyfuse Biomedical's competitors?
Competitors of Cyfuse Biomedical include TWOCELLS.
Compare Cyfuse Biomedical to Competitors
R Bio is a stem cell company that specializes in the research and development of therapeutic agents for diseases with damaged cells and incurable diseases and in providing stem cell banking service for future treatment of diseases using adult tissue-derived stem cells.
TWOCELLS is a regenerative medicine & stem cell company focused on the research, development, manufacture, and sales of therapeutic genes, cells, drugs, diagnostic agents, chemical reagent, and medical materials. In addition, the company engages in the research and development of medical appliances and medical instruments, genes, diagnosis methods, disease treatments and cell culture systems, and computer software systems related to regenerative medicine.
Cellect Biotechnology is a biotechnology company that is developing a novel technology platform known as Powered by Cellect. The company's platform functionally selects stem cells from a mixed population of cells and aims to improve the safety and efficacy of regenerative medicine stem cell therapies.
Cynata Therapeutics is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus. The proprietary Cymerus technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.